Research programme: MEP pathway inhibitors - FerrerAlternative Names: GF-011802-00; GF-011806-00
Latest Information Update: 09 Jan 2009
At a glance
- Originator Ferrer
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Bacterial infections
Most Recent Events
- 09 Jan 2009 Preclinical development is ongoing in Spain
- 24 Jan 2006 Preclinical trials in Bacterial infections in Spain (unspecified route)